GDC 0152

Drug Profile

GDC 0152

Alternative Names: GDC0152; IAP-antagonist - Genentech; IAP-inhibitor - Genentech; RG 7419; Second mitochondrial activator of caspases mimetics - Genentech; SMAC mimetics - Genentech

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 18 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the pharmacokinetics and Cancer pharmacodynamics sections
  • 08 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the Cancer pharmacodynamics section
  • 06 May 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top